JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glatting, G.
Right arrow Articles by Reske, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glatting, G.
Right arrow Articles by Reske, S. N.
Journal of Nuclear Medicine Vol. 47 No. 8 1335-1341
© 2006 by Society of Nuclear Medicine


Basic Science Investigation

Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia

Gerhard Glatting1, Marguerite Müller1, Bernd Koop1, Kathrin Hohl2, Claudia Friesen1, Bernd Neumaier1, Eleanor Berrie3, Pru Bird3, Geoffrey Hale3, Norbert M. Blumstein1, Herman Waldmann3, Donald Bunjes4 and Sven N. Reske1

1 Department of Nuclear Medicine, University Ulm, Ulm, Germany; 2 Department of Biometry and Medical Documentation, University Ulm, Ulm, Germany; 3 Sir William Dunn School of Pathology, Oxford, United Kingdom; and 4 Department of Internal Medicine III (Hematology/Oncology), University Ulm, Ulm, Germany

Correspondence: For correspondence or reprints contact: Gerhard Glatting, PhD, Abteilung Nuklearmedizin, Universität Ulm, D-89070 Ulm, Germany. E-mail: gerhard.glatting{at}uniklinik-ulm.de

The outcome of hematopoietic cell transplantation for hematologic malignancies may be improved by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs. We evaluated the biodistribution of 111In-labeled anti-CD45 antibody in humans using the rat IgG2a monoclonal antibody YAML568 that recognizes a common CD45 epitope present on all human leukocytes. Methods: Eight patients undergoing bone marrow transplantation received YAML568 labeled with 122 ± 16 MBq of 111In intravenously followed by serial blood sampling, urine collection, and conjugated view planar {gamma}-camera imaging up to 144 h after injection. Time–activity curves were obtained using region-of-interest analysis in the accumulating organs and residence times were calculated. An estimate for the radiation-absorbed doses for each organ per unit of administered activity of 90Y was calculated using software for internal dose assessment. The first patient received no unlabeled antibody preloading. The second 2 patients received a preloading dose of 10 mg (0.15 mg/kg). The last 5 patients received a preloading dose of 30–47 mg (0.5 mg/kg). Results: No significant administration-related side effects were seen. The 3 patients receiving no antibody or low antibody preloading had an unfavorable biodistribution with a high initial accumulation of activity in the liver (37%) and the spleen (34%). For the patients receiving 0.5-mg/kg antibody preloading, the estimated radiation-absorbed doses for red bone marrow, spleen, liver, kidney, and total body were 6.4 ± 1.2, 19 ± 5, 3.9 ± 1.4, 1.1 ± 0.4, and 0.6 ± 0.1 mGy/MBq, respectively, demonstrating preferential red marrow targeting. A linear regression model showed that the amount of unlabeled antibody preloading per body weight has a strong influence on the estimated red marrow absorbed dose (P = 0.003, R2 = 0.80). Conclusion: This study shows that the anti-CD45 monoclonal antibody YAML568 is suitable for delivering selectively radiation to hematopoietic tissues when labeled with 90Y provided that a preloading dose of about 0.5 mg/kg unlabeled antibody is given.

Key Words: biodistribution • dosimetry • radiation-absorbed dose • radioimmunotherapy • anti-CD45




This article has been cited by other articles:


Home page
BloodHome page
J. M. Pagel, T. A. Gooley, J. Rajendran, D. R. Fisher, W. A. Wilson, B. M. Sandmaier, D. C. Matthews, H. J. Deeg, A. K. Gopal, P. J. Martin, et al.
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
Blood, December 24, 2009; 114(27): 5444 - 5453.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. U. Louis, K. Straathof, C. M. Bollard, C. Gerken, M. H. Huls, M. V. Gresik, M.-F. Wu, H. L. Weiss, A. P. Gee, M. K. Brenner, et al.
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
Blood, March 12, 2009; 113(11): 2442 - 2450.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. Kletting, D. Bunjes, S. N. Reske, and G. Glatting
Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model
J. Nucl. Med., February 1, 2009; 50(2): 296 - 302.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Pagel, D. C. Matthews, A. Kenoyer, D. K. Hamlin, D. S. Wilbur, D. R. Fisher, A. K. Gopal, Y. Lin, L. Saganic, F. R. Appelbaum, et al.
Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia
Cancer Res., January 1, 2009; 69(1): 185 - 192.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.